Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy

World Journal of Urology

Volumn 34, Issue 9, 2016, Pages 1239-1245

  Henkenberens, Christoph ^a   Merseburger, Axel S ^a   Bengel, Frank ^a   Derlin, Thorsten ^a   Hueper, Katja ^a   Grünwald, Viktor ^a   Christiansen, Hans ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Local control; Lymph node metastases; Radiotherapy; Recurrence prostate cancer

Indexed keywords

AGED; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES;

EID: 84948422911     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-015-1733-y     Document Type: Article

References (31)

1. Merseburger AS, Hammerer P, Rozet F, Roumeguère T, Caffo O, da Silva FC, Alcaraz A (2014) Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy. World J Urol 33(8):1079–1085
2. Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479
3. Abrahamsson PA (2010) Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 57(1):49–59
4. Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G (2013) Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74(3):297–305
5. Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8(6):378–382
6. Schweizer MT, Zhou XC, Wang H et al (2013) Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 24(11):2881–2886
7. Casamassima F, Masi L, Menichelli C et al (2011) Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 97(1):49–55
8. Decaestecker K, Meerleer G, Lambert B et al (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 9:135. doi:10.1186/1748-717X-9-135
9. Ba Jereczek-Fossa, Beltramo G et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82(2):889–897
10. Muacevic A, Kufeld M, Bist C, Wowra B, Stief C, Staehler M (2011) Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases in prostate cancer patients. Urol Oncol 31(4):455–460
11. Schick U, Jorcano S, Nouet P et al (2013) Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastasis. Acta Oncol 52(8):1622–1628
12. National Cancer Institute (2015) Common terminology criteria for adverse events (CTCAE)v.4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 22 Apr 2015
13. Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M (2011) [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 1(6):44. doi:10.1186/1748-717X-6-44
14. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR (2012) Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 22(2):215. doi:10.3389/fonc.2012.00215
15. Picchio M, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G, Fiorino C, Kirienko M, Incerti E, Messa C, Gianolli L, Di Muzio N (2014) (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging 41(7):1270–1279
16. Niyazi M, Bartenstein P, Belka C, Ganswindt U (2010) Choline PET based dose-painting in prostate cancer–modelling of dose effects. Radiat Oncol 18(5):23. doi:10.1186/1748-717X-5-23
17. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P (2004) Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58(1):3–10
18. Malone S, Perry G, Eapen L, Segal R, Gallant V, Dahrouge S et al (2007) Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. Int J Radiat Oncol Bio Phys 68(3):699–706
19. Crook JM, O’Callaghan CJ, Duncan G et al (2012) Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367(10):895–903
20. Yu EY, Gulati R, Telesca D et al (2010) Duration of first off-treatment interval is prognostic for time to castration resistance an death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 28(16):2668–2773
21. Bhandari MS, Crook J, Hussain M (2005) Should intermittent androgen deprivation be uses routinely in clinical practice? J Clin Oncol 23(32):8212–8218
22. Jilg CA, Rischke HC, Reske SN (2012) Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 188(6):2190–2197
23. Suardi N, Gandaglia G, Gallina A et al. (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67(2):299-309
24. Rinnab L, Mottaghy FM, Simon J et al (2008) [11C] Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 81(2):191–197
25. Schalken J, Dijkstra S, Baskin-Bey E, van Oort I (2014) Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. Ther Adv Urol 6(6):245–252
26. Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM (2013) The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64(1):106–117
27. Wondergem M, van der Zant FM, van der Poeg T, Knol RJ (2013) A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-cholie PET/CT for detection of bone metastasis in patients with prostate cancer. Nucl Med Commun 34(10):935–945
28. Abdollah F, Briganti A, Montorsi F et al (2014) Contemporary role of salvage lymhonodectomy in patients with recurrence following radial prostectomy. Eur Urol. doi:10.1016/j.eururo.2014.03.019 (Epub ahead of print)
29. Von Eyben FE, Kairemo K (2014) Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 35(3):221–230
30. Mease RC, Foss CA, Pomper MG (2013) PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem 13(8):951–962
31. Afshar-Oromieh A, Zechman CM, Malcher A, Eder M, Eisenhaut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Mol Imaging 41(1):11–20. doi:10.1007/s00259-013-2525-5 (Epub ahead of print)